Skip to content

Price / book at other companies

Merck & Co. logo
Merck & Co.MRK
6.5×+1.8×
Amgen logo
AmgenAMGN
20.6×-6.3×
Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
6.2×-1.0×
Incyte logo
IncyteINCY
3.3×+0.1×
Johnson & Johnson logo
Johnson & JohnsonJNJ
7.3×+2.1×
United Therapeutics logo
United TherapeuticsUTHR
4.4×+2.4×

Other financials

Income statement

See full
Revenue$3.6B+19.0%
Operating income$642.9M+8.6%
Net income$727.2M-10.1%
EPS (diluted)$6.75-7.1%

Balance sheet

See full
Cash & equivalents$3.0B-4.0%
Total debt$2.7B+0.1%
Total equity$31.4B+6.9%
Total assets$40.9B+8.9%

Cash flow

See full
Operating cash flow$1.1B+3.2%
CapEx$230.6M+0.6%
Free cash flow$848.3M+4.0%

Valuation

See full
Market cap$63.73B+17.8%
Enterprise value$63.47B+18.1%
P/E14.4×+2.4×
P/S4.3×+0.4×

Profitability

See full
Gross margin93.9%
Operating margin24.3%-2.9pp
Net margin29.6%-2.3pp

Returns & leverage

See full
Return on equity14.5%-1.4pp
Debt / equity0.1×0.0×
Current ratio3.6×-1.4×

Where this comes from

Calculated from Regeneron Pharmaceuticals’s reported figures.

Based on the most recent quarter.

The official record: Regeneron Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Regeneron Pharmaceuticals's price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Regeneron Pharmaceuticals's price / book?
Regeneron Pharmaceuticals (REGN) reported price / book of 2.6× in Q1 2026.
How has Regeneron Pharmaceuticals's price / book changed year-over-year?
Regeneron Pharmaceuticals's price / book increased by 10.2% year-over-year, from 2.4× to 2.6×.
What is the long-term trend for Regeneron Pharmaceuticals's price / book?
Over 4 years (2021 to 2025), Regeneron Pharmaceuticals's price / book has grown at a -13.4% compound annual growth rate (CAGR), from 15.6× to 8.8×.
What does price / book mean?
How the market price compares to the company's accounting net worth.
How do you interpret price / book?
Below 1.0 can flag a market discount to book value (common for distressed or asset-heavy firms); high values reflect intangible value the balance sheet doesn't capture. Most informative for financials and asset-heavy businesses.
How does price / book compare across companies?
A core valuation gauge for banks and insurers; weak for asset-light firms where book value understates economic value.